Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 5,842,433
  • Shares Outstanding, K 124,360
  • Annual Sales, $ 346,620 K
  • Annual Income, $ -86,560 K
  • 36-Month Beta 3.14
  • Price/Sales 16.92
  • Price/Cash Flow 0.00
  • Price/Book 27.11

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.75 +7.38%
on 08/11/17
60.01 -21.71%
on 07/25/17
-6.96 (-12.90%)
since 07/18/17
3-Month
42.12 +11.54%
on 05/19/17
60.01 -21.71%
on 07/25/17
+4.74 (+11.22%)
since 05/18/17
52-Week
24.58 +91.13%
on 11/02/16
60.01 -21.71%
on 07/25/17
+12.51 (+36.29%)
since 08/18/16

Most Recent Stories

More News
Biotech Stock Roundup: Regeneron Drops RSV Antibody, Gilead HIV Drug Gets Priority Review

This week, companies like Regeneron (REGN) and Ionis provided updates on their pipeline while Gilead announced priority review for its HIV drug.

CELG : 127.65 (+0.05%)
VRTX : 148.13 (-0.28%)
OPHT : 2.80 (+1.82%)
IONS : 46.98 (-0.36%)
GILD : 72.11 (-0.32%)
REGN : 467.98 (+0.85%)
GLPG : 86.43 (-1.12%)
Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up

Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.

AKCA : 14.10 (-1.47%)
ALNY : 81.42 (+1.42%)
IONS : 46.98 (-0.36%)
GSK : 38.75 (-0.77%)
Featured Company News - GlaxoSmithKline Drops Options to Licence Inotersen and IONIS-FB-LRx; Ionis Pharma to Continue Development Independently

Research Desk Line-up: Amarin Post Earnings Coverage

AMRN : 3.04 (unch)
IONS : 46.98 (-0.36%)
GSK : 38.75 (-0.77%)
Kroll Bond Rating Agency Assigns Preliminary Ratings to UBS 2017-C3

Kroll Bond Rating Agency (KBRA) is pleased to announce the assignment of preliminary ratings to 14 classes of UBS 2017-C3 (see ratings list below), a $708.6 million CMBS conduit transaction...

IONS : 46.98 (-0.36%)
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 11:30...

IONS : 46.98 (-0.36%)
Ionis Pharmaceuticals (IONS) Misses on Q2 Earnings

Ionis Pharmaceuticals' (IONS) reported loss of 9 cents including stock based compensation was wider than expectation. However, sales beat estimates.

IONS : 46.98 (-0.36%)
Ionis Provides Improved 2017 Guidance Following Strong Financial Performance

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported improved financial results with an operating loss of $1.7 million and operating income of $12.3 million for the three and six months ended June...

IONS : 46.98 (-0.36%)
Why Earnings Season Could Be Great for Ionis (IONS)

Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

IONS : 46.98 (-0.36%)
Is a Beat in Store for Ionis (IONS) This Earnings Season?

Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

ESPR : 44.74 (-0.53%)
IONS : 46.98 (-0.36%)
TSRO : 113.86 (+4.41%)
BIIB : 281.77 (-0.93%)
Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency

Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency...

AKCA : 14.10 (-1.47%)
IONS : 46.98 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Support & Resistance

2nd Resistance Point 48.31
1st Resistance Point 47.65
Last Price 46.98
1st Support Level 46.46
2nd Support Level 45.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.